Treatment of acute cryptococcal disease

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 8, 2001, Pages 1259-1268

  Apisarnthanarak, A ^a   Powderly, W G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cryptococcal disease; Cryptococcal meningitis; Fungal disease; Treatment

Indexed keywords

ALPRAZOLAM; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CYCLOSPORIN; DIDANOSINE; FLUCONAZOLE; FLUCYTOSINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LORATADINE; MIDAZOLAM; NORTRIPTYLINE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PYRROLE DERIVATIVE; RIFAMPICIN; SUCRALFATE; SULFONYLUREA; TACROLIMUS; TRIAZOLAM; UNINDEXED DRUG; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE DISEASE; ANATOMY; BONE MARROW SUPPRESSION; BRADYCARDIA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG COST; DRUG FORMULATION; DRUG POTENTIATION; FEVER; FUNGAL MENINGITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HEMATOLOGIC DISEASE; HOST; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHERMIA; IMMUNE STATUS; LIVER TOXICITY; LUNG INFECTION; MALAISE; METABOLIC DISORDER; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; VERTIGO;

ACUTE DISEASE; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; HUMANS; MENINGITIS, CRYPTOCOCCAL;

EID: 0034871077     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.8.1259     Document Type: Review

References (63)

1. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis
2. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis
3. Cryptococcal meningitis and AIDS
4. Practice guidelines for the management of cryptococcal disease
5. Amphotericin B: Current understanding of mechanisms of action
6. Antifungal agents. Part I. Amphotericin B preparations and flucytosine
7. Amphotericin B-associated hypertension
8. Hypothermia following the intravenous administration of amphotericin B
9. Amphotericin-induced heart-rate decrease in children
10. A review of complications of amphotericin B therapy: Recommendations for prevention and management
11. Amphotericin B nephrotoxicity
12. Amphotericin B-induced myelopathy
13. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
14. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks
15. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
16. Pharmacokinetics studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function
17. Flucytosine
18. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis
19. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans
20. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses
21. Pharmacokinetics of itraconazole following oral administration to normal volunteers
22. Treatment of invasive aspergillosis with itraconazole
23. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits
24. Antifungal agents
25. Itraconazole, a novel oral antifungal: Its efficacy and safety profile
26. Adverse events associated with itraconazole in 189 patients on chronic therapy
27. Hepatic injury associated with itraconazole
28. Cryptococcal disease: Implications of recent clinical trials on treatment and management
29. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients. Retrospective analysis of 83 cases
30. Cryptococcosis in HIV-negative patients: Analysis of 306 cases
31. Itraconazole therapy for cryptococal meningitis and cryptococcosis
32. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome
33. Clinical epidemiological study of 171 cases of cryptococcosis
34. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
35. Current approach to the acute management of cryptococcal infections
36. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
37. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis
38. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS
39. Fluconazole combined with flucytosine for the treatment of cryptococcal meningitis in patients with AIDS
40. A Phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis
41. Liposomal amphotericin B (Ambisome) compared with amphotericin B followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
42. Randomized double blind trial of Ambisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients
43. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS
44. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis
45. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
46. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome
47. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis
48. Early mycological treatment failure in AIDS-associated cryptococcal meningitis
49. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing
50. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: Value in the management of AIDS-associated cryptococcal meningitis
51. Amphotericin-B resistant Cryptococcal neoformans in a patient with AIDS
52. The hidden danger of primary fluconazole prophylaxis for patients with AIDS
53. In vitro tumor necrosis factor induction assay for analysis of fabrile toxicity associated with amphotericin B preparations
54. A randomized trial comparing fluconazole with clotrimazole troches for the preventing of fungal infections in patients with advanced human immunodeficiency virus infection
55. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS
56. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study
57. USPHS/IDSA: Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
58. Antibody immunity and invasive fungal infections
59. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis
60. Monoclonal antibodies to Cryptococcal neoformans glucuronoxylomannan enhance fluconazole efficacy
61. Return to the past: The case for antibody-based therapies in infectious diseases
62. The future of antifungal therapy
63. Overview of oral azole drugs as systemic antigungal therapy